As a leading regional CRO, Novotech has been actively involved in hundreds of drug development programs in the Asia Pacific over the past 17 years. Novotech is attending DIA 2013 49th Annual Meeting (Booth #734 Map).

CEO Alek Safarian said Hong Kong and the Philippines were significant markets that were in high demand from USA and EU based pharma and biotech sponsors.

Hong Kong has a long history of attracting global clinical trials having participated in over 1000 global clinical trials.

Other relevant content